A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients

References

• National Comprehensive Cancer Network [homepage on the Internet]NCCN Clinical Practice Guidelines in Oncology: Colon Cancer, version 32014 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed May 20, 2014
   Google Scholar
• Van CutsemECervantesAAdamRESMO consensus guidelines for the management of patients with metastatic colorectal cancerAnn Oncol20162781386142227380959
   PubMed Web of Science ®Google Scholar
• AndréTLouvetCMaindrault-GoebelFCPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOREur J Cancer19993591343134710658525
   PubMed Web of Science ®Google Scholar
• JägerEHeikeMBernhardHWeekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1J Clin Oncol1996148227422798708717
   PubMed Web of Science ®Google Scholar
• FalconeARicciSBrunettiIPhase III trial of infusional fluoro-uracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord OvestJ Clin Oncol200725131670167617470860
   PubMed Web of Science ®Google Scholar
• SouglakosJAndroulakisNSyrigosKFOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)Br J Cancer200694679880516508637
   PubMed Web of Science ®Google Scholar
• CassidyJClarkeSDíaz-RubioERandomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancerJ Clin Oncol200826122006201218421053
   PubMed Web of Science ®Google Scholar
• PetrelliNHerreraLRustumYA prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinomaJ Clin Oncol1987510155915652443619
   PubMed Web of Science ®Google Scholar
• WolmarkNRocketteHFisherBThe benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03J Clin Oncol19931110187918878410113
   PubMed Web of Science ®Google Scholar
• CassidyJTaberneroJTwelvesCXELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancerJ Clin Oncol200422112084209115169795
   PubMed Web of Science ®Google Scholar
• PorschenRArkenauHTKubickaSPhase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study GroupJ Clin Oncol200725274217422317548840
   PubMed Web of Science ®Google Scholar
• SargentDJKöhneCHSanoffHKPooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancerJ Clin Oncol200927121948195519255311
   PubMed Web of Science ®Google Scholar
• ChibaudelBTournigandCBonnetainFTherapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewTher Adv Med Oncol20157315316926673925
   PubMed Web of Science ®Google Scholar
• LeeDJLeeJLeeHYSalvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapyMed Oncol201128Suppl 1291294
   Google Scholar
• JeungHCRhaSYChoBCA phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimensBr J Cancer200695121637164117106441
   PubMed Web of Science ®Google Scholar
• KimSYHongYSKimBCA phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancerInvest New Drugs200927326927418815728
   PubMed Web of Science ®Google Scholar
• MuroKBokuNShimadaYIrinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)Lancet Oncol201011985386020708966
   PubMed Web of Science ®Google Scholar
• ThirionPMichielsSPignonJPModulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysisJ Clin Oncol200422183766377515365073
   PubMed Web of Science ®Google Scholar
• TsukiokaSUchidaJTsujimotoHOral fluoropyrimidine S-1 combined with leucovorin is a promising therapy for colorectal cancer: Evidence from a xenograft model of folate-depleted miceMol Med Rep20092339339821475840
   PubMed Web of Science ®Google Scholar
• KoizumiWBokuNYamaguchiKPhase II study of S-1 plus leucovorin in patients with metastatic colorectal cancerAnn Oncol201021476677119828562
   PubMed Web of Science ®Google Scholar
• OhtsuABabaHSakataYPhase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinomaBr J Cancer200083214114510901361
   PubMed Web of Science ®Google Scholar
• GrotheyAVan CutsemESobreroARegorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialLancet2013381986330331223177514
   PubMed Web of Science ®Google Scholar
• LiJQinSXuRRegorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201516661962925981818
   PubMed Web of Science ®Google Scholar
• MayerRJVan CutsemEFalconeARandomized trial of TAS-102 for refractory metastatic colorectal cancerN Engl J Med2015372201909191925970050
   PubMed Web of Science ®Google Scholar
• GoldbergRMMontagutCWainbergZAOptimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancerESMO Open201834e00035329765773
   PubMed Web of Science ®Google Scholar
• SantiniDVincenziBAddeoRCetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?Ann Oncol20122392313231822396447
   PubMed Web of Science ®Google Scholar
• RossiniDSantiniDCremoliniCPD-026 Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONOAnn Oncol201728Suppl 3iii1iii12
   Google Scholar
• DouillardJYHoffPMSkillingsJRMulticenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200220173605361612202661
   PubMed Web of Science ®Google Scholar
• CarmichaelJPopielaTRadstoneDRandomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancerJ Clin Oncol200220173617362712202662
   PubMed Web of Science ®Google Scholar
• LemberskyBCWieandHSPetrelliNJOral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06J Clin Oncol200624132059206416648506
   PubMed Web of Science ®Google Scholar
• LiJXuRXuJPhase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week offCancer Sci2017108102045205128763145
   PubMed Web of Science ®Google Scholar
• FukushimaMFujiokaAUchidaJNakagawaFTakechiTThymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivoEur J Cancer200137131681168711527696
   PubMed Web of Science ®Google Scholar
• MurakamiYKazunoHEmuraTTsujimotoHSuzukiNFuku-shimaMDifferent mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cellsInt J Oncol200017227728310891536
   PubMed Web of Science ®Google Scholar
• ShirasakaTNakanoKTakechiTAntitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude ratsCancer Res19965611260226068653704
   PubMed Web of Science ®Google Scholar
• YamaguchiKTaniguchiHKomoriAA single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancerBMC Cancer20151560126311588
   PubMed Web of Science ®Google Scholar